Cyfuse Biomedical K.K. Overview
Get informed when a big investor buys or sells
+ Follow-30.35%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Cyfuse Biomedical K.K. (4892.T) currently reports a ROE of -30.35%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore Cyfuse Biomedical K.K.'s ROE history and peer comparisons.
Cyfuse Biomedical K.K.'s ROE of -30.35% is higher than the Healthcare sector average of -75.84%. That is roughly 60.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Cyfuse Biomedical K.K.'s current -30.35% should be judged against Healthcare norms (sector average: -75.84%) and against 4892.T's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -30.35%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Cyfuse Biomedical K.K., and consider following 4892.T for alerts when major investors trade the stock.
Cyfuse Biomedical K.K. is classified in the Healthcare sector. On ROE, it currently shows -30.35% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 4892.T with unrelated industries.
